{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:09:13Z","timestamp":1780625353829,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,9]]},"DOI":"10.7759\/cureus.43197","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T12:33:27Z","timestamp":1691584407000},"source":"Crossref","is-referenced-by-count":9,"title":["Metoprolol or Verapamil in the Management of Patients With Hypertrophic Cardiomyopathy: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Maher","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purva","family":"Dahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Toriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Satnarine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zareen","family":"Zohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ademiniyi","family":"Adelekun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kofi D","family":"Seffah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korlos","family":"Salib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Dardari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana  P","family":"Arcia Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.10.1308","article-title":"Hypertrophic cardiomyopathy: a systematic review","volume":"287","author":"Maron BJ","year":"2002","unstructured":"Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002, 287:1308-20. 10.1001\/jama.287.10.1308","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.07.074","article-title":"What is the true prevalence of hypertrophic cardiomyopathy?","volume":"66","author":"Baudhuin LM","year":"2015","unstructured":"Baudhuin LM, Kotzer KE, Kluge ML, Maleszewski JJ. What is the true prevalence of hypertrophic cardiomyopathy?. J Am Coll Cardiol. 2015, 66:1845-6. 10.1016\/j.jacc.2015.07.074","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian AJ","year":"2017","unstructured":"Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017, 121:749-70. 10.1161\/CIRCRESAHA.117.311059","journal-title":"Circ Res"},{"key":"ref4","unstructured":"MedlinePlus. Familial hypertrophic cardiomyopathy. (2023). Accessed: April 23, 2023: https:\/\/medlineplus.gov\/genetics\/condition\/familial-hypertrophic-cardiomyopathy\/."},{"key":"ref5","article-title":"Section II: the organization, structure, and function of muscle","author":"Riddle DL","year":"1997","unstructured":"Riddle DL, Blumenthal T, Meyer BJ, et al.. Section II: the organization, structure, and function of muscle. C. elegans II, 2nd edition. Cold Spring Harbor Laboratory Press, Long Island, NY; 1997. 33:417-70."},{"key":"ref6","unstructured":"American Heart Association, Inc.. Hypertrophic cardiomyopathy (HCM). (2023). Accessed: April 23, 2023: https:\/\/www.heart.org\/en\/health-topics\/cardiomyopathy\/what-is-cardiomyopathy-in-adults\/hypertrophic-cardiomyopathy."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/heart.86.6.709","article-title":"Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy","volume":"86","author":"Wigle ED","year":"2001","unstructured":"Wigle ED. Cardiomyopathy: the diagnosis of hypertrophic cardiomyopathy. Heart. 2001, 86:709-14. 10.1136\/heart.86.6.709","journal-title":"Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.17.611","article-title":"Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study","volume":"17","author":"Sakamoto T","year":"1976","unstructured":"Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle. Echocardiographic and ultrasono-cardiotomographic study. Jpn Heart J. 1976, 17:611-29. 10.1536\/ihj.17.611","journal-title":"Jpn Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90135-a","article-title":"Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making","volume":"20","author":"Grigg LE","year":"1992","unstructured":"Grigg LE, Wigle ED, Williams WG, Daniel LB, Rakowski H. Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992, 20:42-52. 10.1016\/0735-1097(92)90135-a","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(00)01019-6","article-title":"Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy","volume":"36","author":"Yu EH","year":"2000","unstructured":"Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: relationship to obstruction and relief with myectomy. J Am Coll Cardiol. 2000, 36:2219-25. 10.1016\/s0735-1097(00)01019-6","journal-title":"J Am Coll Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.97.5.461","article-title":"Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy","volume":"97","author":"Kizilbash AM","year":"1998","unstructured":"Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation. 1998, 97:461-6. 10.1161\/01.cir.97.5.461","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000000304","article-title":"Left ventricular outflow tract obstruction in ICU patients","volume":"22","author":"Slama M","year":"2016","unstructured":"Slama M, Tribouilloy C, Maizel J. Left ventricular outflow tract obstruction in ICU patients. Curr Opin Crit Care. 2016, 22:260-6. 10.1097\/MCC.0000000000000304","journal-title":"Curr Opin Crit Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10396-021-01116-z","article-title":"How to standardize the measurement of left ventricular ejection fraction","volume":"49","author":"Kusunose K","year":"2022","unstructured":"Kusunose K, Zheng R, Yamada H, Sata M. How to standardize the measurement of left ventricular ejection fraction. J Med Ultrason (2001). 2022, 49:35-43. 10.1007\/s10396-021-01116-z","journal-title":"J Med Ultrason (2001)"},{"key":"ref14","unstructured":"MSD Manual Professional Edition. Hypertrophic cardiomyopathy. (2022). Accessed: April 23, 2023: https:\/\/www.msdmanuals.com\/professional\/cardiovascular-disorders\/cardiomyopathies\/hypertrophic-cardiomyopathy."},{"key":"ref15","article-title":"Metoprolol","author":"Morris J","year":"2022","unstructured":"Morris J, Dunham A. Metoprolol. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref16","article-title":"Verapamil","author":"Fahie S","year":"2023","unstructured":"Fahie S, Cassagnol M. Verapamil. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro AM","year":"2021","unstructured":"Dybro AM, Rasmussen TB, Nielsen RR, Andersen MJ, Jensen MK, Poulsen SH. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2021, 78:2505-17. 10.1016\/j.jacc.2021.07.065","journal-title":"J Am Coll Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90386-f","article-title":"A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy","volume":"21","author":"Gilligan DM","year":"1993","unstructured":"Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, Oakley CM. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993, 21:1672-9. 10.1016\/0735-1097(93)90386-f","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1536\/ihj.27.701","article-title":"Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study","volume":"27","author":"Toshima H","year":"1986","unstructured":"Toshima H, Koga Y, Nagata H, Toyomasu K, Itaya K, Matoba T. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. Jpn Heart J. 1986, 27:701-15. 10.1536\/ihj.27.701","journal-title":"Jpn Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14142","article-title":"Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature","volume":"10","author":"Bayonas-Ruiz A","year":"2023","unstructured":"Bayonas-Ruiz A, Mu\u00f1oz-Franco FM, Sabater-Molina M, Oliva-Sandoval MJ, Gimeno JR, Bonacasa B. Current therapies for hypertrophic cardiomyopathy: a systematic review and meta-analysis of the literature. ESC Heart Fail. 2023, 10:8-23. 10.1002\/ehf2.14142","journal-title":"ESC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/159192-metoprolol-or-verapamil-in-the-management-of-patients-with-hypertrophic-cardiomyopathy-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:53Z","timestamp":1707508913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/159192-metoprolol-or-verapamil-in-the-management-of-patients-with-hypertrophic-cardiomyopathy-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.43197","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,9]]}}}